The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the Nasdaq AlphaDEX® Large Cap Growth Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is designed to select growth stocks from the NASDAQ US 500 Large Cap Index (the base index) that may generate positive alpha, or risk-adjusted returns, relative to traditional indices through the use of the AlphaDEX® selection methodology.
Inception Date: 08/05/2007
Primary Benchmark: NASDAQ AlphaDEX(R) LC Growth TR USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 0.62%
Management Expense Ratio: 0.61 %
|BNTX||BioNTech SE||0.00 %||
|FREQ||Frequency Therapeutics, Inc||0.00 %||
|HBT||HBT Financial, Inc||0.00 %||
|OPRT||Oportun Financial Corporation||0.00 %||
|VIE||Viela Bio, Inc||0.00 %||
|VIR||Vir Biotechnology, Inc||0.00 %||
|ALFC||Alfacourse Inc||0.00 %||
|AMRQQ||Alta Mesa Resources, Inc||0.00 %||
|AMRWQ||Alta Mesa Resources, Inc||0.00 %||
|BSML||Invesco BulletShares (R) 2021 ..||0.00 %||
|Market Performance vs.
|Market Performance vs. Exchange|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||9.74%||55%||F||88%||B+|
|Risk Adjusted Return||98.55%||85%||B||92%||A-|
|Letter Grade||Percentage||Letter Grade||Percentage||Letter Grade||Percentage|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.